Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Weizmannia Coagulans BC99 Gummy Alleviates Pediatric Allergic Rhinitis Via Modulating Gut Metabolism

NCT06885632 is registered in ClinicalTrials.gov with Wecare Probiotics Co., Ltd. as lead sponsor.

NCT NCT06885632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06885632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Weizmannia Coagulans BC99 Gummy Alleviates Pediatric Allergic Rhinitis Via Modulating Gut Metabolism
Lead sponsor
Wecare Probiotics Co., Ltd.
Phase
Not applicable
Overall status
Completed
Start date
October 10, 2024
Completion date
August 20, 2025
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

children with allergic rhinitis